Anzeige
Erschienen in:
01.04.2016 | Neuro
Apparent diffusion coefficient parametric response mapping MRI for follow-up of glioblastoma
Erschienen in: European Radiology | Ausgabe 4/2016
Einloggen, um Zugang zu erhaltenAbstract
Objectives
To determine the diagnostic superiority of parametric response mapping of apparent diffusion coefficient (ADCPR) for predicting glioblastoma treatment response, compared to single time point measurement.
Methods
Fifty post-treatment glioblastoma patients were enrolled. ADCPR was calculated from serial apparent diffusion coefficient (ADC) maps acquired before and at the time of first detection of an enlarged contrast-enhancing lesion on voxel-by-voxel basis. The percentage-decrease in ADCPR and tenth percentile histogram cutoff value of ADC (ADC10) were compared at subsequent 3-month and 1-year follow-ups.
Results
The percentage-decrease in ADCPR was significantly higher in the progression group (mean = 33.2–38.3 %) than in the stable-response group (mean = 9.7 %) at 3 months follow-up (corrected p < 0.001 for both readers). ADCPR significantly improved area under the receiver operating characteristic curve from 0.67 to 0.88 (corrected p = 0.037) and from 0.70 to 0.92 (corrected p = 0.020) for both readers, respectively, compared to ADC10 at 3-month follow-up, but did not significantly improve at 1-year follow-up. The inter-reader agreement was higher for ADCPR than ADC10 (intraclass correlation coefficient, 0.93 versus 0.86).
Conclusion
Voxel-based ADCPR appears to be a superior imaging biomarker than ADC, particularly for predicting early tumour progression in patients with glioblastoma.
Key points
• Treatment response pattern of glioblastoma was evaluated using voxel-based ADCPR and ADC10.
• Voxel-based ADCPR was more accurate in predicting treatment response pattern than ADC10.
• Inter-reader agreement was higher in ADCPR calculation than in ADC10 calculation.
• Voxel-based ADCPR can be a predictor of early treatment response pattern for glioblastoma.